Ramsay Health Care vs Sonic Healthcare shares

If you’re weighing up Ramsay Health Care Ltd (ASX: RHC) and Sonic Healthcare Ltd (ASX: SHL) shares, you’re not alone — these two are among the brightest lights in Australian healthcare. Yet, their business models, dividend policies and current market valuations are quite different. For value-seeking investors, there’s a lot to unpack, so let’s compare their fundamentals, dividend history, recent share price performance and what I think is the smarter buy right now.

The case for Ramsay Health Care

Ramsay Health Care is one of the world’s largest private hospital operators, with a vast portfolio spanning around 500 facilities — including hospitals, day surgeries, clinics, and mental health services — across 11 countries. Beyond Australia, Ramsay has substantial operations in Europe and the UK, and, according to its company profile, derives most of its revenue from Australia and Europe. This makes it a genuine global healthcare heavyweight, with a long track record in running complex, capital-intensive medical infrastructure.

A couple of key numbers stand out. First, Ramsay’s market cap sits at $12.58 billion, above Sonic’s, marking it as the larger of the two companies. Its P/E ratio is 41.00, reflecting a rich valuation, especially compared to most of the market. Dividend hunters will note its 1.63% yield, but every cent of that payout is fully franked (100%). Its dividend per share for the most recent period was $0.97, again, all franked.

The case for Sonic Healthcare

Sonic Healthcare is a global leader in pathology and diagnostic services. It’s the largest private medical laboratory and pathology provider in key markets including Australia, the UK, Germany, and Switzerland. Most of Sonic’s revenue comes from pathology, but the business also has a significant footprint in diagnostic imaging and medical centre operations in Australia, making it a diversified diagnostics powerhouse.

Fundamentally, Sonic’s story right now is quite different to Ramsay’s. Its market capitalisation is $9.20 billion, a fair bit smaller than Ramsay’s. But here’s where things get interesting for value investors: its P/E ratio is 15.44, easily less than half of Ramsay’s, suggesting Sonic shares are much more modestly valued at current earnings levels. Its dividend yield is a chunky 5.69%, and while only 60% franked for the latest payout, that’s still a potentially appealing income stream. Recent dividends have totalled $1.08 per share.

Valuation comparison

With several key differences apparent, here’s how Ramsay and Sonic line up on the numbers that matter for value-focused investors:

Metric	Ramsay Health Care	Sonic Healthcare
Market Cap	$12.58 billion	$9.20 billion
P/E Ratio	41.00	15.44
Dividend Yield	1.63% (100% franked)	5.69% (60% franked)
Dividend per share (most recent)	$0.97	$1.08
Earnings per share	1.358	1.230
Year to Date Return	64.7%	-11.2%

Note: Ramsay’s reported P/E ratio may be based on a different earnings measure (e.g. underlying or forward earnings) than the EPS figure shown, which is why they may appear inconsistent.

Simply put, if I’m judging pure valuation metrics, Sonic Healthcare looks much more attractively priced relative to its earnings and offers a much higher dividend yield, albeit with less franking than Ramsay. Ramsay’s high P/E suggests the market is baking in a lot of future growth or sees it as much lower risk — or possibly a bit of both.

Recent share price momentum

Comparing recent share price performance up to1 October 2026:

• Ramsay Health Care closed at $54.48 on 1 Oct 2026, down 2.16% on the day but boasting impressive momentum over 2026 with a year-to-date return of 64.7%.
• Sonic Healthcare finished at $18.61 on 1 Oct 2026, also dropping 2.00% that day, and is down 11.2% for the year to date.

Over the past year, Ramsay has surged ahead and Sonic has gone backwards. For investors looking for momentum and the market’s latest vote of confidence, Ramsay clearly wears the crown for 2026 so far.

Which is the better buy?

For me, as a value-seeking investor, Sonic Healthcare is the better buy right now. Here’s why: Sonic’s P/E ratio of 15.44 is far lower than Ramsay’s 41.00, and yet its earnings per share are pretty similar. Even better, Sonic’s dividend yield is well over three times Ramsay’s (5.69% vs 1.63%), though franking is only 60% versus Ramsay’s full 100%.

Ramsay has had a great run this year, reflected in its huge year-to-date return, but that’s precisely why I’d be cautious about buying it now – it’s probably priced for perfection. Sonic, meanwhile, has lagged in the share price stakes and may well be out of favour, but it’s this relative unloved status that gives it value appeal. Its business is less capital intensive, cash-generative and, in my eyes, looks like a classic opportunity for patient investors to scoop up a top ASX healthcare stock at a fair valuation, with a strong, fully-funded dividend yield to boot.

So, if I had to buy one for value today, my pick would be Sonic Healthcare.

The post Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value? appeared first on The Motley Fool Australia.

More reading

• Where I’d invest in ASX shares after the recent RBA rate rise
• Buy, hold, sell: Woodside, Life360, Ramsay Health Care shares
• Expert names ‘undervalued’ ASX 200 healthcare stock to buy today
• 5 things to watch on the ASX 200 on Thursday
• Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial draft. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

ASX shares are climbing higher on Tuesday afternoon as investor jitters calm, oil prices fall, and gold edges higher.

Here are three ASX shares that brokers expect will help drive the share market higher over the next 12 months.

And one of them is tipped to jump 322%!

Generation Development Group Ltd (ASX: GDG)

The diversified financial services company’s shares have consistently and continually tumbled lower over the past year. 

At the time of writing, they’re trading for $2.68 each, down around 55% for the year to date and 63% lower than an all-time high in October last year. 

It looks like the share price decline is mostly investors taking their gains off the table after a strong rally through 2025.

The company itself continues to perform well. Its FY26 results showed Generation Development Group is performing well operationally. The company posted record funds under management of $6.5 billion in August, which is a 37% year-on-year increase. 

Its underlying NPAT also increased 21% to $40.7 million, and group revenue climbed 23% to $178.7 million.

The company also said that it thinks it is well-placed to benefit from strong structural tailwinds across superannuation, retirement, and managed account markets in FY27. Management expects continued FUM growth, supported by adviser adoption and stable product revenue margins.

Brokers are very optimistic that the shares can stage a turnaround. Market Index data shows that all brokers agree on a strong buy rating on the ASX shares. The $5.62 average target price implies about 109% upside at the time of writing.

Wildcat Resources Ltd (ASX: WC8)

The ASX lithium shares are down 2% for the day at the time of writing, trading at 27 cents each. That’s a 28% decline for the year to date, but the shares are still trading around 30% higher than 12 months ago.

In late August, the company reported strong lithium drill results at its Bolt Cutter Central and Tabba Tabba projects in WA. The company has identified multiple high-grade lithium drill intersections across Bolt Cutter Central and Tabba Tabba, including 16m at 1.5% Li₂O and 13.9m at 2.0% Li₂O.

The company is focused on delivering a maiden Mineral Resource Estimate for Bolt Cutter Central and advancing technical studies at Tabba Tabba, set for release in the second half of 2026. 

Wildcat is also targeting key new drill regions for further resource upgrades in the months ahead.

Experts are optimistic that Wildcat can reach its Tabba Tabba lithium project milestones and expand its Bolt Cutter discovery.

The company is also expected to benefit from an improving lithium market. If lithium demand from EVs and battery storage keeps rising, the ASX shares could benefit from a boom in demand.

Market Index data shows that all brokers have a strong buy rating on the shares. The $1.15 average target price implies a potential 322% upside, at the time of writing. 

Deep Yellow Ltd (ASX: DYL)

Deep Yellow is an ASX uranium development company with a portfolio of Australian and global projects. At the time of writing, its shares are down around 0.5% for the day, to an annual low of $1.09 a piece. For the year to date, the shares are now down around 44% and 46% lower than 12 months ago.

Rising bond yields and higher interest rates have acted as strong headwinds for ASX uranium shares over the past year. Uranium developers like Deep Yellow need upfront capital, and it takes several years to become profitable. Investors have also been rotating towards more stable or defensive assets in times of volatility.

It’s not all bad news, though. In August, the company announced it had completed two major milestones at its flagship Tumas Project in Namibia. These included a long-term water supply agreement and finalisation of local ownership arrangements. The company is now focused on successfully progressing its Tumas Project towards a Final Investment Decision in Q4 2026.

Brokers are also bullish that the ASX shares can keep climbing. Market Index data shows the majority have a strong buy rating, and the $2.28 average target price implies an upside of around 109% at the time of writing.

The post 3 ASX shares tipped to fly 109% to 322% higher appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Deep Yellow, SGH, Telstra shares
• This ASX uranium stock could rise 40%: Broker
• 4 ASX shares tipped by brokers to return 63% to 125%
• Why is this ASX lithium stock crashing 10% on Monday?
• 3 ASX shares trading at 52-week lows that could be outstanding value plays 

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Generation Development Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Commonwealth Bank of Australia (ASX: CBA) shares are down slightly in Tuesday lunchtime trade.

At the time of writing, the ASX bank shares are down around 0.1% to $151.11 each. Today’s decline means the shares are down around 7% over the past month, and around 6% lower for the year to date.

For context, the S&P/ASX 200 Index (ASX: XJO) is up around 0.5% for the day, at the time of writing. This index is down around 3% over the past month and largely flat for the year to date.

The question now is, are CBA shares a buy? Or will any investment made today turn into an inevitable loss by October 2027?

Let’s take a look.

Analyst outlooks on CBA shares

Higher oil prices, a stubbornly high inflation rate, a tight jobs market, and the potential for more interest rate increases are all strong headwinds for CBA over the next 12 months.

And brokers aren’t too positive on the outlook for the bank shares going forward.

Market Index data shows all experts have a strong sell rating on the shares. The $125.20 average target price implies a downside of around 17% at the time of writing.

The data is similar on TradingView. The majority of analysts (14 out of 16) have a sell or strong sell rating on CBA shares. Another two rate the bank shares as a hold.

The average $128.29 target price implies the shares could fall around 15% over the next 12 months. Although some are even more bearish and think they have the potential to crash around 40% to $90 by this time next year, at the time of writing.

So, if I buy $10,000 of CBA shares today, what could they be worth by this time next year?

If broker forecasts come to fruition, a $10,000 investment in CBA shares today could be worth significantly less by October 2027. Average downsides of 15% to 17% could see $10,000 turn into $8,300 to $8,500 within the next 12 months.

If the more bearish expert forecasts come to fruition, a $10,000 investment today could drop to $6,000 by this time next year.

Does that mean investors should avoid buying CBA shares?

If capital gain is your plan, CBA shares might not be for you at the current trading price.

But there are some other reasons that the bank shares could still make for a good investment. 

Its large scale and strong operational performance means the company has the potential to be resilient through times of economic volatility, and its cyclical nature also means it can outperform during times of recovery.

And this is fantastic news for passive income-seeking investors.

CBA has a long history of paying its shareholders regular fully-franked dividends dating back to 1992. These are typically paid out every six months, in March and September.

The bank most recently paid its shareholders a $2.70-per-share fully-franked final dividend and a fully-franked full-year dividend of $5.05. That translates to a yield of around 3.3%.

Forecasts suggest the bank will pay its shareholders closer to $5.45 per share in FY27, which translates to a forward dividend yield of roughly 3.6%.

So while your $10,000 investment might not rocket higher in value, you could still earn a tidy passive income off of it. 

Using the current trading price and forecasted $5.45 per share dividend in FY27, I’ve calculated that you could earn around $360 in passive income off a $10,000 investment in FY27.

The post If I invest $10,000 in CBA shares today, what could they be worth in October 2027? appeared first on The Motley Fool Australia.

More reading

• How much could the big 4 banks’ share prices fall?
• Buy, hold, sell: CBA, Capstone Copper, Codan shares
• Why I’d buy CBA and Coles shares in October
• If I invest $10,000 in ANZ shares, what passive income could I receive in FY27?
• Are ASX 200 bank stocks a buy in October?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.